Search results for: “24”

Goal and Focus A formal working group within CPIC, PharmGKB, PharmVar, and the PGRN was formed in 2018 to focus on the dissemination of resources available for pharmacogenetic implementation such as CPIC guidelines, PharmGKB, PGRN and PharmVar resources, and implementation strategies of pharmacogenetics. The goal of the CPIC Dissemination Working Group is to support the…

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019) Updates since publication: October 2019: CYP2D6 genotype to phenotype translation changes: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype across guidelines (i.e. CPIC and DPWG) and between clinical genetic…

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (January 2018) Updates since publication: October 2019: CYP2D6 genotype to phenotype translation changes: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype across guidelines (i.e. CPIC and DPWG) and between clinical genetic…

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016) Updates since publication: October 2019: CYP2D6 genotype to phenotype translation changes: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype across guidelines (i.e. CPIC and DPWG)…

ClinPGx 2024 Meeting Registration open In collaboration with CPIC, PharmGKB, PharmCAT and PharmVar, the Penn Institute for Biomedical Informatics will be hosting the ClinPGx 2024: Knowledge, Implementation, Education meeting on June 20th and 21st, 2024 in Philadelphia, PA. This meeting will provide educational content to cover all aspects of PGx implementation. Participants are invited to submit…

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020) Updates since publication: No updates on dosing recommendations since publication. Tables and figure provided in the main manuscript of the guideline: Table 1. Assignment of likely HLA-B phenotypes based on genotypes Table 2. Assignment of…

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update (December 2016) Updates since publication: No updates on dosing recommendations since this publication. Figures provided in the main manuscript of the guideline: Figure 1. Schematic representation of warfarin metabolism and its mechanism of action. Figure 2. Dosing recommendations for…

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014) Updates since publication: No updates on dosing recommendations since publication. Tables provided in the main manuscript of the guideline: Table 1 Assignment of probable IFNL3 phenotypes based on genotypes Table 2 Recommendations for use of…

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype (March 2014) Updates since publication: May 2019: The FDA-approved drug label for ivacaftor has been updated to include additional variants, bringing the total number of indicated variants to 38. The CPIC guideline supplement and CFTR Allele…

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020) Tables and figure provided in the main manuscript of the guideline: Table 1. Assignment of predicted CYP2D6 phenotypes based on diplotypes Table 2. Codeine therapy recommendations based on CYP2D6 phenotype Table 3. Tramadol…